Therefore, many DMD gene therapy studies utilize the microdystrophin (μDys) gene, a shorter (3.7 kbp) functional version of the dystrophin gene, which has been demonstrated to cause DMD to present as a much less severe dystrophy with a longer life expectancy and higher quality of life [12,13,14]. The gene discussed is DMD; the disease is Duchenne muscular dystrophy.